Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
NCT04364776
·
clinicaltrials.gov ↗
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Lung Cancer Stage III
Interventions
DRUG:
Durvalumab
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia